SCHEMBL16845430

SCHEMBL16845430

COc1ccc(Cl)cc1NC[C@H]1C[C@@H]1c1ccc(S(N)(=O)=O)cc1

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.50
▸ LMNA P02545 4/20 0.50
▸ MEN1 O00255 3/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ CA2 P00918 6/20 0.45
▸ CA1 P00915 5/20 0.45
▸ CA9 Q16790 2/20 0.45
▸ TP53 P04637 1/20 0.45
▸ NLRP3 Q96P20 1/20 0.44
▸ ACHE P22303 1/20 0.42
▸ RXFP1 Q9HBX9 1/20 0.42
▸ CA12 O43570 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ CA14 Q9ULX7 1/20 0.42
▸ MAPK1 P28482 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ DRD4 P21917 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15557156 1.00 ALDH1A1 (0.50) ALDH1A1LMNAMEN1KMT2ACA2
SCHEMBL20707912 0.84 DRD4 (0.44) ALDH1A1LMNAMEN1KMT2ATP53
SCHEMBL16845401 0.84 ALDH1A1 (0.54) ALDH1A1LMNAMEN1KMT2ACA2
SCHEMBL15556294 0.84 ALDH1A1 (0.54) ALDH1A1LMNAMEN1KMT2ACA2
SCHEMBL16819984 0.81 LMNA (0.50) ALDH1A1LMNAMEN1KMT2ACA2
SCHEMBL18938292 0.81 LMNA (0.50) ALDH1A1LMNAMEN1KMT2ACA2
SCHEMBL16819911 0.81 LMNA (0.50) ALDH1A1LMNAMEN1KMT2ACA2
SCHEMBL16819969 0.81 LMNA (0.50) ALDH1A1LMNAMEN1KMT2ACA2
SCHEMBL29467331 0.81 LMNA (0.50) ALDH1A1LMNAMEN1KMT2ACA2
SCHEMBL18889002 0.81 CA1 (0.46) ALDH1A1LMNAMEN1KMT2ACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790173-B2 Alpha-7 nicotinic acetylcholine receptor modulators and uses thereof-I MERCK SHARP & DOHME CORP. (US) 2017-10-17 — — US disclosed
US-20170158628-A1 ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I MERCK SHARP & DOHME CORP. (US) 2017-06-08 — — US disclosed
US-20150175534-A1 Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I MERCK SHARP & DOHME CORP. 2015-06-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170158628-A1 ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF-I CHRNA7, CHRNA5, CHRNA6 ALDH1A1 846/4885LMNA 2675/4885MEN1 3964/4885
US-20150175534-A1 Alpha-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEROF-I CHRNA7, CHRNA6, CHRNA5 ALDH1A1 1762/4885LMNA 3119/4885MEN1 3873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback